A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Docetaxel
  • Indications Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RANGE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
    • 31 May 2017 According to an Eli Lilly media release, detailed efficacy and safety results will be submitted for presentation at a future medical meeting. Final overall survival (OS) results are currently expected in mid-2018.
    • 31 May 2017 Primary endpoint (Progression Free Survival) has been met according to an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top